Panoramic Capital LLC Makes New $2.72 Million Investment in Pulse Biosciences, Inc $PLSE

Panoramic Capital LLC acquired a new stake in Pulse Biosciences, Inc (NASDAQ:PLSE) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 98,054 shares of the company’s stock, valued at approximately $2,719,000. Pulse Biosciences accounts for 1.2% of Panoramic Capital LLC’s investment portfolio, making the stock its 24th largest position.

Several other large investors have also recently added to or reduced their stakes in the business. Russell Investments Group Ltd. grew its holdings in Pulse Biosciences by 13.8% in the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after buying an additional 619 shares during the period. BNP Paribas Financial Markets grew its holdings in Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after purchasing an additional 680 shares during the period. Osterweis Capital Management Inc. purchased a new position in Pulse Biosciences during the second quarter worth approximately $28,000. Alliancebernstein L.P. boosted its holdings in shares of Pulse Biosciences by 6.7% in the 3rd quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock valued at $365,000 after purchasing an additional 1,300 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after buying an additional 2,156 shares during the period. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on PLSE. Needham & Company LLC initiated coverage on Pulse Biosciences in a research report on Monday, August 17th. They issued a “buy” rating and a $58.00 target price on the stock. Wall Street Zen lowered Pulse Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Mizuho set a $45.00 target price on Pulse Biosciences in a report on Monday, August 10th. Finally, Canaccord Genuity Group increased their target price on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $45.25.

Pulse Biosciences Trading Down 1.8%

Shares of Pulse Biosciences stock opened at $48.10 on Thursday. Pulse Biosciences, Inc has a twelve month low of $12.56 and a twelve month high of $50.90. The stock has a market cap of $3.33 billion, a price-to-earnings ratio of -40.76 and a beta of 1.61. The company has a fifty day moving average price of $34.48 and a 200 day moving average price of $26.66.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The company had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. Analysts forecast that Pulse Biosciences, Inc will post -1.29 earnings per share for the current year.

Pulse Biosciences Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.